Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK/PD of CKD-508 in Healthy Adults
NCT04488900Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKD-508 in dyslipidemia (8 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Safety and tolerability including treatment-emergent AE and treatment-emergent SAE. Started Jul 2020; status: completed.
02
Drugs
CKD-508
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04488900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488900.